Emerging research suggest Retatrutide , a dual activator targeting both incretin and another hormone, could represent a promising development for obesity loss . Preliminary human investigations have indicated considerable losses in visceral mass , possibly outperforming existing body composition therapies . Despite this, more assessment is required